MX2013007588A - Comprimido de desintegracion oral. - Google Patents

Comprimido de desintegracion oral.

Info

Publication number
MX2013007588A
MX2013007588A MX2013007588A MX2013007588A MX2013007588A MX 2013007588 A MX2013007588 A MX 2013007588A MX 2013007588 A MX2013007588 A MX 2013007588A MX 2013007588 A MX2013007588 A MX 2013007588A MX 2013007588 A MX2013007588 A MX 2013007588A
Authority
MX
Mexico
Prior art keywords
fine granules
active ingredient
pharmaceutically active
lansoprazole
controlled release
Prior art date
Application number
MX2013007588A
Other languages
English (en)
Inventor
Takayuki Okabe
Shiro Ishii
Yutaka Ebisawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45509604&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013007588(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MX2013007588A publication Critical patent/MX2013007588A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Abstract

Se proporciona un comprimido de desintegración oral obtenido por compresión de gránulos finos que muestran una liberación controlada de lansoprazol y un aditivo, que es capaz de suprimir la rotura de los gránulos finos durante la compresión y puede controlar la liberación de lansoprazol durante un tiempo prolongado y puede mantener una concentración terapéuticamente efectiva durante un tiempo prolongado y muestra una propiedad de desintegración en la cavidad oral. Un comprimido de desintegración oral que contiene (i) gránulos finos que muestran una liberación controlada de un ingrediente farmacéuticamente activo, que contiene gránulos finos con un ingrediente farmacéuticamente activo y una capa de recubrimiento con copolímero de ácido metacrílico/acrilato de metilo/metacrilato de metilo, en donde los gránulos finos que contienen un ingrediente farmacéuticamente activo están recubiertos con más del 80% en peso y no más del 300% en peso del copolímero y (ii) gránulos finos que muestran una liberación controlada de un ingrediente farmacéuticamente activo, que contiene el ingrediente farmacéuticamente activo y una capa de recubrimiento que comprende (a) un copolímero de acrilato de etilo/metacrilato de metilo y (b) uno o varios tipos de polimeros seleccionados del grupo que consiste en copolímero de ácido metacrílico/acrilato de etilo, ftalato de hipromelosa, carboximetiletilcelulosa, acetato ftalato de polivinilo, acetato succinato de hidroxipropilmetilcelu losa y acetato ftalato de celulosa, en donde los gránulos finos (i) y gránulos finos (ii) tienen un tamaño de partícula medio de no más deI 500 µm y el ingrediente farmacéuticamente activo es lansoprazol o una de sus formas ópticamente activos o una de sus sales.
MX2013007588A 2010-12-27 2011-12-26 Comprimido de desintegracion oral. MX2013007588A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061427384P 2010-12-27 2010-12-27
PCT/JP2011/080568 WO2012091153A2 (en) 2010-12-27 2011-12-26 Orally disintegrating tablet

Publications (1)

Publication Number Publication Date
MX2013007588A true MX2013007588A (es) 2013-08-09

Family

ID=45509604

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007588A MX2013007588A (es) 2010-12-27 2011-12-26 Comprimido de desintegracion oral.

Country Status (23)

Country Link
US (1) US20130273157A1 (es)
EP (1) EP2658530A2 (es)
JP (1) JP2014501224A (es)
KR (1) KR20140007364A (es)
CN (1) CN103402500A (es)
AR (1) AR084610A1 (es)
AU (1) AU2011350396A1 (es)
BR (1) BR112013014875A2 (es)
CA (1) CA2823166C (es)
CL (1) CL2013001793A1 (es)
CO (1) CO6731132A2 (es)
CR (1) CR20130327A (es)
EA (1) EA028217B1 (es)
EC (1) ECSP13012718A (es)
MA (1) MA34768B1 (es)
MX (1) MX2013007588A (es)
PE (1) PE20141115A1 (es)
SG (2) SG10201602311XA (es)
TN (1) TN2013000220A1 (es)
TW (1) TW201304823A (es)
UY (1) UY33841A (es)
WO (1) WO2012091153A2 (es)
ZA (1) ZA201304617B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009113703A2 (en) 2008-03-11 2009-09-17 Takeda Pharmaceutical Company Limited Orally-disintegrating solid preparation
PT2797416T (pt) 2011-12-28 2017-10-23 Global Blood Therapeutics Inc Compostos de benzaldeído substituído e métodos para a sua utilização no aumento da oxigenação de tecidos
ES2790358T3 (es) 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
GB201303781D0 (en) 2013-03-04 2013-04-17 Gauthier Pierre Pascal Oral timer device and method of using same
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CN105073728A (zh) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
AP2015008718A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
MY180206A (en) 2013-03-15 2020-11-25 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
DK3102208T3 (da) 2014-02-07 2021-03-08 Global Blood Therapeutics Inc Krystallinsk polymorf af den frie base af 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyd
CA2966631A1 (en) 2014-11-14 2016-05-19 Gemphire Therapeutics Inc. Processes and intermediates for preparing alpha, omega-dicarboxylic acid-terminated dialkane ethers
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
MA43373A (fr) 2015-12-04 2018-10-10 Global Blood Therapeutics Inc Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde
AR108435A1 (es) 2016-05-12 2018-08-22 Global Blood Therapeutics Inc Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
TWI778983B (zh) * 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
US20190008779A1 (en) * 2017-05-11 2019-01-10 Gemphire Therapeutics Inc. Gemcabene compositions and methods of use thereof
WO2019013310A1 (en) * 2017-07-10 2019-01-17 Takeda Pharmaceutical Company Limited PREPARATION COMPRISING VONOPRAZAN
CN108576205B (zh) * 2018-03-22 2022-01-04 湖北省农业科学院农产品加工与核农技术研究所 一种草莓联合干燥的处理方法
WO2020072377A1 (en) 2018-10-01 2020-04-09 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
JPH072761B2 (ja) 1985-03-20 1995-01-18 不二パウダル株式会社 微結晶セルロ−ス球形顆粒及びその製造法
JPS62277322A (ja) 1986-02-13 1987-12-02 Takeda Chem Ind Ltd 安定化された腸溶性抗潰瘍固形組成物
FR2679451B1 (fr) 1991-07-22 1994-09-09 Prographarm Laboratoires Comprime multiparticulaire a delitement rapide.
JP3069458B2 (ja) 1992-01-29 2000-07-24 武田薬品工業株式会社 口腔内崩壊型錠剤およびその製造法
JP2919771B2 (ja) 1995-04-17 1999-07-19 佐藤製薬株式会社 速溶解性錠剤の製造方法及び該製造方法により製造した速溶解性錠剤
JPH0948726A (ja) 1995-08-07 1997-02-18 Tanabe Seiyaku Co Ltd 口腔内速崩壊性製剤およびその製法
TW385306B (en) 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
JP3828648B2 (ja) 1996-11-14 2006-10-04 武田薬品工業株式会社 ２−（２−ピリジルメチルスルフィニル）ベンズイミダゾール系化合物の結晶およびその製造法
DK1736144T3 (en) 1998-05-18 2015-12-07 Takeda Pharmaceutical Orally disintegrating tablets.
ATE481090T1 (de) 1998-07-28 2010-10-15 Takeda Pharmaceutical Leicht zerfallende feste zubereitung
TWI275587B (en) 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
DE60124692T2 (de) 2000-04-28 2007-09-13 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von optisch-aktiven sulfoxid-derivaten
CA2762960C (en) 2000-05-15 2014-07-22 Takeda Pharmaceutical Company Limited Recrystallization processes for obtaining anhydrous optically active lansoprazole
KR100887912B1 (ko) 2000-12-01 2009-03-12 다케다 야쿠힌 고교 가부시키가이샤 (ｒ)- 또는 (ｓ)-란소프라졸의 결정화 방법
JP4493970B2 (ja) 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
CA2558535A1 (en) * 2004-03-03 2005-10-06 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical composition comprising an acid labile drug
US20070141151A1 (en) * 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
WO2007078271A2 (en) * 2005-12-20 2007-07-12 Teva Pharmaceutical Industries Ltd. Lansoprazole orally disintegrating tablets
EP1837016A3 (en) * 2006-03-08 2008-01-02 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical multiple-unit composition
WO2008081891A1 (ja) * 2006-12-28 2008-07-10 Takeda Pharmaceutical Company Limited 口腔内崩壊性固形製剤
WO2009113703A2 (en) * 2008-03-11 2009-09-17 Takeda Pharmaceutical Company Limited Orally-disintegrating solid preparation
US20100015239A1 (en) * 2008-07-17 2010-01-21 Ahmed Salah U Orally Disintegrating Solid Pharmaceutical Dosage Forms Comprising Delayed-Release Lansoprazole and Methods of Making and Using the Same

Also Published As

Publication number Publication date
ZA201304617B (en) 2014-08-27
WO2012091153A3 (en) 2012-09-07
SG190905A1 (en) 2013-07-31
EA028217B1 (ru) 2017-10-31
ECSP13012718A (es) 2013-12-31
JP2014501224A (ja) 2014-01-20
EP2658530A2 (en) 2013-11-06
KR20140007364A (ko) 2014-01-17
EA201390981A1 (ru) 2014-07-30
TW201304823A (zh) 2013-02-01
WO2012091153A2 (en) 2012-07-05
CA2823166A1 (en) 2012-07-05
PE20141115A1 (es) 2014-09-12
CR20130327A (es) 2013-08-22
UY33841A (es) 2012-07-31
MA34768B1 (fr) 2013-12-03
TN2013000220A1 (en) 2014-11-10
AU2011350396A1 (en) 2013-07-11
US20130273157A1 (en) 2013-10-17
CO6731132A2 (es) 2013-08-15
CL2013001793A1 (es) 2013-12-06
SG10201602311XA (en) 2016-04-28
CA2823166C (en) 2019-04-09
CN103402500A (zh) 2013-11-20
AR084610A1 (es) 2013-05-29
BR112013014875A2 (pt) 2016-10-18

Similar Documents

Publication Publication Date Title
TN2013000220A1 (en) Orally disintegrating tablet
MX2022002952A (es) Formulaciones de liberacion modificada de 2-[3-[4-amino-3-(2-fluor o-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbo nil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enenitrilo.
JP2019147832A5 (es)
JP2010270128A5 (es)
NZ591688A (en) Dosage form comprising time-pulsatile release beads
RU2015110824A (ru) Фармацевтическая или нутрицевтическая композиция с замедленным высвобождением и стойкостью к воздействию этанола
CA2797812A1 (en) Enteric tablet
NZ588499A (en) Controlled-release particles with core comprising a weakly basic drug and a controlled-release coating
JP2013522219A5 (es)
RU2014131238A (ru) Состав с отсроченным высвобождением для уменьшения частоты мочеиспускания и способ его применения
TW200624126A (en) New modified release tablet formulations for proton pump inhibitors
WO2011107855A3 (en) Sustained release oral liquid suspension dosage form
RU2012136839A (ru) Композиции для ухода за полостью рта и устранения неприятного запаха
JP2015506359A5 (es)
TW200624127A (en) New modified release pellet formulations for proton pump inhibitors
JP2014533656A5 (es)
WO2012053785A3 (ko) 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛
KR20160010595A (ko) 구강내 붕괴정
CA2797809A1 (en) Enteric tablet
EP2641594B1 (en) Enteric coated solid pharmaceutical compositions for proton pump inhibitors
NZ599742A (en) Improved oral pharmaceutical solid dosage form
CN103751137B (zh) 雷诺嗪多单元缓释微丸片
CA2733299A1 (en) Oral pharmaceutical formulation for omeprazole comprising a specific separation layer
TN2014000177A1 (en) Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation
CA2433915A1 (en) Improved controlled release oral dosage form

Legal Events

Date Code Title Description
FA Abandonment or withdrawal